Variability in Response to Cardiovascular Drugs

Author(s): Ehab S. ELDesoky, Hartmut Derendorf, Ulrich Klotz

Journal Name: Current Clinical Pharmacology
Continued as Current Reviews in Clinical and Experimental Pharmacology

Volume 1 , Issue 1 , 2006


Cardiovascular drugs are characterized by wide inter-individual variability in dose/plasma concentration/ response (therapeutic and/or toxic) relationships. Therefore, some patients achieve good therapeutic response to their drug therapy, while others do not. Also, some patients experience adverse effects, which vary from mild to life-threatening. The source of variability in patients response to cardiovascular drugs may be of pharmacokinetic and/or pharmacodynamic origin. Many factors can potentially affect both of them such as genetics, gender, age, disease state, environmental factors like smoking and food, possible drug-drug interactions, and ethnicity (race). Cardiovascular pharmacogenomics is a new field that focus on the roles of genetic polymorphisms in drug metabolizing enzymes and drug targets in development of variable drug response.

Keywords: CYP2D6 enzyme, pharmacodynamic, P-glycoprotein (Pgp), MDR-1 gene, Hepatic disease, Carvedilol, Angiotensin Converting Enzyme Inhibitors

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [35 - 46]
Pages: 12
DOI: 10.2174/157488406775268273

Article Metrics

PDF: 31